Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin

Updated 06/21/2024

Status Active, not recruiting

Clinical Trial Summary

This study will evaluate the efficacy of Pixantrone with rituximab, ifosfamide and etoposide as measured by the overall metabolic response rate after 2 cycles of treatment or at permanent treatment discontinuation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03458260
Study type	Interventional
Source	The Lymphoma Academic Research Organisation
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	March 26, 2018
Completion date	March 2025

See also
	Status	Clinical Trial	Phase
	Completed	`NCT01527045` - Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies	Phase 2
	Completed	`NCT03161054` - Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas	Phase 2
	Recruiting	`NCT03246906` - Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation	Phase 2
	Suspended	`NCT04231877` - Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma	Phase 1
	Active, not recruiting	`NCT00075478` - Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer	Phase 3
	Completed	`NCT00789776` - Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer	Phase 1/Phase 2
	Completed	`NCT01231412` - Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant	Phase 3
	Suspended	`NCT03704714` - Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma	Phase 1/Phase 2
	Completed	`NCT03061188` - Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma	Phase 1
	Recruiting	`NCT01787409` - Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency	N/A
	Active, not recruiting	`NCT03035331` - Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma	Phase 1/Phase 2
	Completed	`NCT00723099` - Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	Phase 2
	Withdrawn	`NCT04372641` - Testing the Safety of CB-5339 in Patients With Cancer	Phase 1
	Recruiting	`NCT05336409` - A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies	Phase 1
	Active, not recruiting	`NCT03749018` - Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma	Phase 2
	Recruiting	`NCT05260957` - CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).	Phase 2
	Completed	`NCT01251575` - Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant	Phase 2